Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study)

Summary

Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill, in HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA \<50 copies/mL

Timeline

Start

2021-03-23

Primary completion

2023-04-01

Completion

2024-04-01

Drugs

Indications